Emergent Biosolutions Stock Price, News & Analysis (NYSE:EBS)

$41.68 0.81 (1.98 %)
(As of 11/24/2017 04:00 PM ET)
Previous Close$40.87
Today's Range$40.62 - $41.87
52-Week Range$25.96 - $44.86
Volume251,175 shs
Average Volume335,757 shs
Market Capitalization$1.69 billion
P/E Ratio21.62
Dividend YieldN/A
Beta1.22

About Emergent Biosolutions (NYSE:EBS)

Emergent Biosolutions logoEmergent BioSolutions Inc. is a life sciences company. The Company focuses on protecting and enhancing life by providing specialty products for civilian and military populations that address accidental, intentional and naturally emerging public health threats. It focuses on developing, manufacturing and commercializing medical countermeasures that address public health threats (PHTs). The PHTs operates through two categories: Chemical, Biological, Radiological and Nuclear, as well as explosive-related threats and emerging infectious diseases. It operates through four business units: Vaccines and Anti-infectives; Antibody Therapeutics; Devices, and Contract Manufacturing. Vaccines and Anti-infectives business unit consists of BioThrax, which is for the general use prophylaxis and post-exposure prophylaxis of anthrax disease. Devices business unit consists of marketed products, such as Reactive Skin Decontamination Lotion Kit (RSDL) and Trobigard (atropine sulfate, obidoxime chloride).

Receive EBS News and Ratings via Email

Sign-up to receive the latest news and ratings for EBS and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceuticals
Sub-IndustryBiotechnology
SectorHealthcare
SymbolNYSE:EBS
CUSIP29089Q10
Phone240-631-3200

Debt

Debt-to-Equity Ratio0.38%
Current Ratio7.37%
Quick Ratio6.46%

Price-To-Earnings

Trailing P/E Ratio21.62
Forward P/E Ratio25.41
P/E Growth1.13

Sales & Book Value

Annual Sales$488.78 million
Price / Sales3.53
Cash Flow$2.91 per share
Price / Cash14.31
Book Value$16.03 per share
Price / Book2.60

Profitability

Trailing EPS$1.69
Net Income$51.77 million
Net Margins22.45%
Return on Equity20.96%
Return on Assets13.49%

Miscellaneous

Employees1,098
Outstanding Shares41,400,000

Frequently Asked Questions for Emergent Biosolutions (NYSE:EBS)

What is Emergent Biosolutions' stock symbol?

Emergent Biosolutions trades on the New York Stock Exchange (NYSE) under the ticker symbol "EBS."

How were Emergent Biosolutions' earnings last quarter?

Emergent Biosolutions, Inc. (NYSE:EBS) announced its quarterly earnings results on Thursday, November, 2nd. The biopharmaceutical company reported $0.73 earnings per share for the quarter, beating analysts' consensus estimates of $0.41 by $0.32. The biopharmaceutical company had revenue of $149.43 million for the quarter, compared to the consensus estimate of $124.55 million. Emergent Biosolutions had a net margin of 22.45% and a return on equity of 20.96%. Emergent Biosolutions's revenue for the quarter was up 4.6% on a year-over-year basis. During the same period last year, the company posted $0.56 EPS. View Emergent Biosolutions' Earnings History.

When will Emergent Biosolutions make its next earnings announcement?

Emergent Biosolutions is scheduled to release their next quarterly earnings announcement on Wednesday, February, 21st 2018. View Earnings Estimates for Emergent Biosolutions.

Where is Emergent Biosolutions' stock going? Where will Emergent Biosolutions' stock price be in 2017?

3 Wall Street analysts have issued 12-month target prices for Emergent Biosolutions' shares. Their predictions range from $43.00 to $47.00. On average, they anticipate Emergent Biosolutions' share price to reach $45.00 in the next twelve months. View Analyst Ratings for Emergent Biosolutions.

What are Wall Street analysts saying about Emergent Biosolutions stock?

Here are some recent quotes from research analysts about Emergent Biosolutions stock:

  • 1. According to Zacks Investment Research, "Emergent’s follow-on contract with the CDC and deals with the BARDA for BioThrax and NuThrax (the next-generation anthrax vaccine candidate) bodes well for growth. NuThrax’s approval will be a huge boost for the company. We are also positive on Emergent’s spin-off of its biosciences business into a separate publicly traded company as it is expected to result in a reduced cost structure. Shares of the company have outperformed the broader industry so far this year. On the flip side, the company’s sole dependence on BioThrax for its revenue is concerning. Meanwhile, Emergent faces competition from a number of companies with Biodefense products. However, the U.S. government is the primary purchaser of BioThrax which is a big boost to the company. Estimates have been going up lately ahead of the company’s Q3 earnings release. The company has positive record of earnings surprises in recent quarters." (10/25/2017)
  • 2. Cowen Inc analysts commented, "Emergent BioSolutions pre-announced 2016 financials at the high end of the guidance." (1/9/2017)

Who are some of Emergent Biosolutions' key competitors?

Who are Emergent Biosolutions' key executives?

Emergent Biosolutions' management team includes the folowing people:

  • Fuad El-Hibri, Executive Chairman of the Board
  • Daniel J. Abdun-Nabi, President, Chief Executive Officer, Director
  • Robert G. Kramer Sr., Chief Financial Officer, Executive Vice President, Administration, Treasurer
  • Adam Havey, Executive Vice President - Business Operations
  • Ronald B. Richard, Lead Independent Director
  • Sue Bailey M.D., Independent Director
  • Zsolt Harsanyi Ph.D., Independent Director
  • Jerome M. Hauer Ph.D., Independent Director
  • George A. Joulwan USA, Independent Director

Who owns Emergent Biosolutions stock?

Emergent Biosolutions' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Dimensional Fund Advisors LP (5.37%), Rice Hall James & Associates LLC (1.56%), Schwab Charles Investment Management Inc. (1.49%), Peregrine Capital Management LLC (1.10%), Russell Investments Group Ltd. (1.10%) and Fisher Asset Management LLC (1.05%). Company insiders that own Emergent Biosolutions stock include Adam Havey, Daniel Abdun-Nabi, Fuad El-Hibri, George A Joulwan, Jerome M Hauer, Louis W Sullivan, Marvin L White, Robert Kramer, Ronald Richard, Sue Bailey and Zsolt Harsanyi. View Institutional Ownership Trends for Emergent Biosolutions.

Who sold Emergent Biosolutions stock? Who is selling Emergent Biosolutions stock?

Emergent Biosolutions' stock was sold by a variety of institutional investors in the last quarter, including Schwab Charles Investment Management Inc., New York State Common Retirement Fund, Rice Hall James & Associates LLC, Strs Ohio, Virginia Retirement Systems ET AL, First Trust Advisors LP, GSA Capital Partners LLP and Teachers Retirement System of The State of Kentucky. Company insiders that have sold Emergent Biosolutions company stock in the last year include Adam Havey, Daniel Abdun-Nabi, Fuad El-Hibri, George A Joulwan, Jerome M Hauer, Ronald Richard and Sue Bailey. View Insider Buying and Selling for Emergent Biosolutions.

Who bought Emergent Biosolutions stock? Who is buying Emergent Biosolutions stock?

Emergent Biosolutions' stock was purchased by a variety of institutional investors in the last quarter, including Peregrine Capital Management LLC, New Amsterdam Partners LLC NY, Convergence Investment Partners LLC, Chicago Equity Partners LLC, Systematic Financial Management LP, Fisher Asset Management LLC, Insight Capital Research & Management Inc. and Comerica Bank. View Insider Buying and Selling for Emergent Biosolutions.

How do I buy Emergent Biosolutions stock?

Shares of Emergent Biosolutions can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Emergent Biosolutions' stock price today?

One share of Emergent Biosolutions stock can currently be purchased for approximately $41.68.

How big of a company is Emergent Biosolutions?

Emergent Biosolutions has a market capitalization of $1.69 billion and generates $488.78 million in revenue each year. The biopharmaceutical company earns $51.77 million in net income (profit) each year or $1.69 on an earnings per share basis. Emergent Biosolutions employs 1,098 workers across the globe.

How can I contact Emergent Biosolutions?

Emergent Biosolutions' mailing address is 400 PROFESSIONAL DR SUITE 400, GAITHERSBURG MD, 20879. The biopharmaceutical company can be reached via phone at 240-631-3200 or via email at [email protected]


MarketBeat Community Rating for Emergent Biosolutions (EBS)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  149 (Vote Outperform)
Underperform Votes:  120 (Vote Underperform)
Total Votes:  269
MarketBeat's community ratings are surveys of what our community members think about Emergent Biosolutions and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Analysts' Consensus Rating for Emergent Biosolutions (NYSE:EBS)

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.862.862.712.80
Ratings Breakdown: 0 Sell Rating(s)
1 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $40.67$40.67$39.40$39.40
Price Target Upside: 1.46% upside1.46% upside9.17% upside30.68% upside

Consensus Price Target History for Emergent Biosolutions (NYSE:EBS)

Price Target History for Emergent Biosolutions (NYSE:EBS)

Analysts' Ratings History for Emergent Biosolutions (NYSE:EBS)

Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
9/30/2017Wells Fargo & CompanyReiterated RatingOutperform$41.00 -> $43.00MediumView Rating Details
1/30/2017Chardan CapitalReiterated RatingBuy$47.00N/AView Rating Details
1/9/2017Cowen IncReiterated RatingHoldN/AView Rating Details
8/5/2016J P Morgan Chase & CoLower Price TargetOverweight$45.00 -> $36.00N/AView Rating Details
6/28/2016Singular ResearchLower Price TargetBuy$44.00 -> $40.00N/AView Rating Details
(Data available from 11/24/2015 forward)

Earnings

Earnings History and Estimates Chart for Emergent Biosolutions (NYSE:EBS)

Earnings by Quarter for Emergent Biosolutions (NYSE:EBS)

Earnings History by Quarter for Emergent Biosolutions (NYSE EBS)

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/21/2018$0.64N/AView Earnings Details
11/2/2017Q3 2017$0.41$0.73$124.55 million$149.43 millionViewN/AView Earnings Details
8/3/2017Q2 2017$0.26$0.13$111.57 million$100.77 millionViewListenView Earnings Details
5/4/2017Q1 2017$0.31$0.23$121.30 million$116.90 millionViewListenView Earnings Details
2/23/2017Q4 2016$0.48$0.74$120.45 million$151.66 millionViewListenView Earnings Details
11/7/2016Q3$0.26$0.58$112.30 million$142.91 millionViewListenView Earnings Details
8/4/2016Q2($0.17)($0.18)$111.20 million$101.49 millionViewListenView Earnings Details
5/5/2016Q1($0.07)$0.16$101.83 million$111.00 millionViewListenView Earnings Details
2/25/2016Q4$0.69$0.78$168.07 million$168.10 millionViewListenView Earnings Details
11/5/2015Q315$0.55$0.83$151.42 million$164.90 millionViewListenView Earnings Details
8/6/2015Q215$0.18$0.36$114.25 million$126.10 millionViewListenView Earnings Details
5/7/2015Q1($0.46)($0.50)$62.70 million$63.60 millionViewListenView Earnings Details
3/5/2015Q115$0.97$0.75$147.00 million$148.00 millionViewListenView Earnings Details
11/6/2014Q414$0.37$0.67$126.90 million$138.00 millionViewListenView Earnings Details
8/7/2014Q214$0.26$0.24$109.25 million$110.30 millionViewListenView Earnings Details
5/8/2014Q114($0.34)($0.40)$57.30 million$53.90 millionViewListenView Earnings Details
3/6/2014Q413$0.36$0.42$93.83 million$94.10 millionViewListenView Earnings Details
11/7/2013Q313$0.21$0.37$79.13 million$89.10 millionViewListenView Earnings Details
8/5/2013Q2 2013$0.21$0.29$75.73 million$82.40 millionViewListenView Earnings Details
5/2/2013Q1 2013($0.14)($0.22)$46.17 million$43.10 millionViewListenView Earnings Details
3/7/2013Q4 2012$0.44$0.44$95.09 million$94.61 millionViewListenView Earnings Details
11/1/2012Q312$0.22$0.18$73.53 million$66.60 millionViewN/AView Earnings Details
8/2/2012$0.21$0.21ViewN/AView Earnings Details
5/3/2012($0.18)($0.19)ViewN/AView Earnings Details
3/8/2012$0.72$0.78ViewN/AView Earnings Details
11/3/2011($0.04)$0.04ViewN/AView Earnings Details
8/4/2011$0.33$0.40ViewN/AView Earnings Details
5/5/2011($0.52)($0.64)ViewN/AView Earnings Details
3/10/2011$0.67$0.76ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Emergent Biosolutions (NYSE:EBS)
Current Year EPS Consensus Estimate: $1.64 EPS
Next Year EPS Consensus Estimate: $2.17 EPS

Dividends

Dividend History for Emergent Biosolutions (NYSE:EBS)

No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Emergent Biosolutions (NYSE EBS)

Insider Ownership Percentage: 16.50%
Institutional Ownership Percentage: 86.09%
Insider Trades by Quarter for Emergent Biosolutions (NYSE:EBS)
Institutional Ownership by Quarter for Emergent Biosolutions (NYSE:EBS)

Insider Trades by Quarter for Emergent Biosolutions (NYSE EBS)

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
11/14/2017Fuad El-HibriChairmanSell40,000$40.37$1,614,800.00View SEC Filing  
11/7/2017George A JoulwanDirectorSell14,251$41.24$587,711.24View SEC Filing  
11/3/2017Daniel Abdun-NabiCEOSell31,508$42.77$1,347,597.16View SEC Filing  
9/29/2017Fuad El-HibriChairmanSell25,000$40.50$1,012,500.00View SEC Filing  
9/28/2017Ronald RichardDirectorSell22,415$40.00$896,600.00View SEC Filing  
9/27/2017Adam HaveyEVPSell7,885$39.50$311,457.50View SEC Filing  
9/27/2017Daniel Abdun-NabiCEOSell15,000$39.92$598,800.00View SEC Filing  
9/27/2017Fuad El-HibriChairmanSell25,000$39.50$987,500.00View SEC Filing  
9/27/2017Ronald RichardDirectorSell1,266$40.00$50,640.00View SEC Filing  
9/14/2017Fuad El-HibriChairmanSell25,000$38.50$962,500.00View SEC Filing  
9/8/2017Adam HaveyEVPSell7,885$37.06$292,218.10View SEC Filing  
9/7/2017Fuad El-HibriChairmanSell16,439$37.50$616,462.50View SEC Filing  
9/5/2017Fuad El-HibriChairmanSell3,100$37.50$116,250.00View SEC Filing  
8/31/2017Daniel Abdun-NabiCEOSell15,000$37.21$558,150.00View SEC Filing  
8/31/2017Fuad El-HibriChairmanSell5,461$37.50$204,787.50View SEC Filing  
8/15/2017Jerome M HauerDirectorSell10,776$35.83$386,104.08View SEC Filing  
7/27/2017Fuad El-HibriChairmanSell25,000$36.50$912,500.00View SEC Filing  
7/20/2017Fuad El-HibriChairmanSell25,000$35.50$887,500.00View SEC Filing  
4/3/2017Adam HaveyEVPSell11,419$28.62$326,811.78View SEC Filing  
3/8/2017Jerome M HauerDirectorSell2,576$31.27$80,551.52View SEC Filing  
1/17/2017Adam HaveyEVPSell8,438$29.75$251,030.50View SEC Filing  
1/17/2017Sue BaileyDirectorSell19,424$29.78$578,446.72View SEC Filing  
1/10/2017Daniel Abdun-NabiInsiderSell28,240$31.28$883,347.20View SEC Filing  
12/13/2016Ronald RichardDirectorSell5,900$34.09$201,131.00View SEC Filing  
6/6/2016George A JoulwanDirectorSell4,700$44.12$207,364.00View SEC Filing  
6/1/2016Daniel Abdun-NabiCEOSell8,699$43.74$380,494.26View SEC Filing  
5/27/2016Fuad El-HibriMajor ShareholderSell9,835$43.50$427,822.50View SEC Filing  
5/26/2016Fuad El-HibriMajor ShareholderSell39,759$43.13$1,714,805.67View SEC Filing  
5/25/2016Fuad El-HibriMajor ShareholderSell85,000$42.52$3,614,200.00View SEC Filing  
5/25/2016Zsolt HarsanyiDirectorSell27,867$42.33$1,179,610.11View SEC Filing  
5/24/2016Fuad El-HibriChairmanSell20,000$42.26$845,200.00View SEC Filing  
5/23/2016Fuad El-HibriChairmanSell45,000$42.62$1,917,900.00View SEC Filing  
5/20/2016Daniel Abdun-NabiCEOSell8,701$42.00$365,442.00View SEC Filing  
5/19/2016Jerome M HauerDirectorSell3,134$41.22$129,183.48View SEC Filing  
5/13/2016Louis W SullivanDirectorSell47,631$39.21$1,867,611.51View SEC Filing  
5/12/2016Fuad El-HibriMajor ShareholderSell25,000$38.71$967,750.00View SEC Filing  
5/12/2016Jerome M HauerDirectorSell4,700$38.50$180,950.00View SEC Filing  
5/11/2016Louis W SullivanDirectorSell9,969$39.25$391,283.25View SEC Filing  
4/22/2016Fuad El-HibriMajor ShareholderSell4,209$40.50$170,464.50View SEC Filing  
4/18/2016Daniel Abdun-NabiCEOSell8,702$40.17$349,559.34View SEC Filing  
4/18/2016Fuad El-HibriMajor ShareholderSell20,791$40.50$842,035.50View SEC Filing  
4/6/2016Fuad El-HibriMajor ShareholderSell50,000$39.00$1,950,000.00View SEC Filing  
4/6/2016Robert KramerEVPSell21,786$38.90$847,475.40View SEC Filing  
4/4/2016Robert KramerEVPSell21,788$36.90$803,977.20View SEC Filing  
4/1/2016Robert KramerEVPSell43,572$35.56$1,549,420.32View SEC Filing  
3/14/2016Adam HaveyEVPSell4,359$33.96$148,031.64View SEC Filing  
3/14/2016Jerome M HauerDirectorSell2,350$33.88$79,618.00View SEC Filing  
3/11/2016Adam HaveyEVPSell11,112$33.84$376,030.08View SEC Filing  
3/11/2016Louis W SullivanDirectorSell14,879$34.03$506,332.37View SEC Filing  
3/7/2016Marvin L WhiteDirectorSell33,134$35.42$1,173,606.28View SEC Filing  
1/4/2016Sue BaileyDirectorSell11,520$38.79$446,860.80View SEC Filing  
12/30/2015Ronald RichardDirectorSell21,600$40.00$864,000.00View SEC Filing  
12/24/2015Daniel Abdun-NabiCEOSell63,209$39.06$2,468,943.54View SEC Filing  
11/19/2015Fuad El-Hibrimajor shareholderSell17,871$37.50$670,162.50View SEC Filing  
11/13/2015Fuad El-Hibrimajor shareholderSell13,013$36.50$474,974.50View SEC Filing  
11/12/2015Barry LabingerEVPSell36,126$35.64$1,287,530.64View SEC Filing  
11/9/2015Fuad El-Hibrimajor shareholderSell13,225$35.50$469,487.50View SEC Filing  
11/6/2015Fuad El-Hibrimajor shareholderSell13,450$34.50$464,025.00View SEC Filing  
11/3/2015Fuad El-Hibrimajor shareholderSell13,689$33.50$458,581.50View SEC Filing  
9/11/2015Sue BaileyDirectorSell6,080$32.37$196,809.60View SEC Filing  
8/13/2015George A JoulwanDirectorSell7,200$34.72$249,984.00View SEC Filing  
7/20/2015Fuad El-HibriChairmanSell234$34.50$8,073.00View SEC Filing  
7/13/2015Ronald RichardDirectorSell4,922$34.00$167,348.00View SEC Filing  
6/29/2015Ronald RichardDirectorSell4,923$32.76$161,277.48View SEC Filing  
6/22/2015Fuad El-HibriMajor ShareholderSell74,564$32.60$2,430,786.40View SEC Filing  
6/16/2015Louis W SullivanDirectorSell13,457$31.33$421,607.81View SEC Filing  
6/15/2015Adam HaveyEVPSell36,298$31.55$1,145,201.90View SEC Filing  
6/15/2015Fuad El-HibriMajor ShareholderSell45,436$32.18$1,462,130.48View SEC Filing  
1/20/2015Fuad El-HibriMajor ShareholderSell15,325$27.67$424,042.75View SEC Filing  
12/26/2014Ronald RichardDirectorSell5,000$28.00$140,000.00View SEC Filing  
12/17/2014Ronald RichardDirectorSell5,000$27.00$135,000.00View SEC Filing  
12/11/2014Fuad El-HibriMajor ShareholderSell119,341$26.00$3,102,866.00View SEC Filing  
11/28/2014Fuad El-HibriMajor ShareholderSell34,577$25.00$864,425.00View SEC Filing  
11/25/2014Fuad El-HibriMajor ShareholderSell9,014$25.00$225,350.00View SEC Filing  
11/25/2014Zsolt HarsanyiDirectorSell8,000$24.82$198,560.00View SEC Filing  
11/12/2014Fuad El-HibriMajor ShareholderSell2,311$25.00$57,775.00View SEC Filing  
11/7/2014Robert KramerCFOSell2,625$24.00$63,000.00View SEC Filing  
4/16/2014Robert KramerCFOSell50,189$24.34$1,221,600.26View SEC Filing  
3/12/2014Adam HaveyEVPSell11,562$27.50$317,955.00View SEC Filing  
3/11/2014Adam HaveyEVPSell17,655$26.96$475,978.80View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Emergent Biosolutions (NYSE EBS)

Source:
DateHeadline
Emergent BioSolutions, Inc. breached its 50 day moving average in a Bullish Manner : EBS-US : November 23, 2017Emergent BioSolutions, Inc. breached its 50 day moving average in a Bullish Manner : EBS-US : November 23, 2017
finance.yahoo.com - November 23 at 4:18 PM
Emergent BioSolutions Receives FDA Approval to Manufacture ACAM2000 at Canton, Massachusetts Facility - GlobeNewswire (press release)Emergent BioSolutions Receives FDA Approval to Manufacture ACAM2000 at Canton, Massachusetts Facility - GlobeNewswire (press release)
globenewswire.com - November 20 at 11:58 PM
Emergent BioSolutions (EBS) Receives FDA Approval to Manufacture ACAM2000 at Canton, Massachusetts FacilityEmergent BioSolutions (EBS) Receives FDA Approval to Manufacture ACAM2000 at Canton, Massachusetts Facility
www.streetinsider.com - November 20 at 6:58 PM
Emergent BioSolutions Receives FDA Approval to Manufacture ACAM2000 at Canton, Massachusetts FacilityEmergent BioSolutions Receives FDA Approval to Manufacture ACAM2000 at Canton, Massachusetts Facility
finance.yahoo.com - November 20 at 6:58 PM
Emergent BioSolutions: More Than An Emerging Biotech - Seeking AlphaEmergent BioSolutions: More Than An Emerging Biotech - Seeking Alpha
seekingalpha.com - November 16 at 1:41 PM
Fuad El-Hibri Sells 40,000 Shares of Emergent Biosolutions, Inc. (EBS) StockFuad El-Hibri Sells 40,000 Shares of Emergent Biosolutions, Inc. (EBS) Stock
www.americanbankingnews.com - November 15 at 7:57 PM
Emergent BioSolutions Announces Notice of Termination of Conversion Rights of 2.875% Convertible Senior Notes ... - NasdaqEmergent BioSolutions Announces Notice of Termination of Conversion Rights of 2.875% Convertible Senior Notes ... - Nasdaq
www.nasdaq.com - November 15 at 4:34 AM
Emergent BioSolutions Announces Notice of Termination of Conversion Rights of 2.875% Convertible Senior Notes ... - GlobeNewswire (press release)Emergent BioSolutions Announces Notice of Termination of Conversion Rights of 2.875% Convertible Senior Notes ... - GlobeNewswire (press release)
globenewswire.com - November 14 at 11:32 PM
Emergent BioSolutions Announces Notice of Termination of Conversion Rights of 2.875% Convertible Senior Notes Due 2021Emergent BioSolutions Announces Notice of Termination of Conversion Rights of 2.875% Convertible Senior Notes Due 2021
finance.yahoo.com - November 14 at 6:31 PM
$175.41 Million in Sales Expected for Emergent Biosolutions, Inc. (EBS) This Quarter$175.41 Million in Sales Expected for Emergent Biosolutions, Inc. (EBS) This Quarter
www.americanbankingnews.com - November 11 at 12:00 PM
Emergent BioSolutions, Inc. breached its 50 day moving average in a Bullish Manner : EBS-US : November 9, 2017Emergent BioSolutions, Inc. breached its 50 day moving average in a Bullish Manner : EBS-US : November 9, 2017
finance.yahoo.com - November 10 at 7:51 AM
Perrigo (PRGO) Q3 Earnings Top, 2017 View Raised, Shares UpPerrigo (PRGO) Q3 Earnings Top, 2017 View Raised, Shares Up
finance.yahoo.com - November 10 at 7:51 AM
Emergent Biosolutions, Inc. (EBS) Director Sells $587,711.24 in StockEmergent Biosolutions, Inc. (EBS) Director Sells $587,711.24 in Stock
www.americanbankingnews.com - November 9 at 7:04 PM
Financial Survey: Emergent Biosolutions (EBS) vs. Marinus Pharmaceuticals (MRNS)Financial Survey: Emergent Biosolutions (EBS) vs. Marinus Pharmaceuticals (MRNS)
www.americanbankingnews.com - November 9 at 3:52 PM
ETFs with exposure to Emergent BioSolutions, Inc. : November 8, 2017ETFs with exposure to Emergent BioSolutions, Inc. : November 8, 2017
finance.yahoo.com - November 9 at 1:45 AM
 Brokerages Anticipate Emergent Biosolutions, Inc. (EBS) Will Post Earnings of $0.71 Per Share Brokerages Anticipate Emergent Biosolutions, Inc. (EBS) Will Post Earnings of $0.71 Per Share
www.americanbankingnews.com - November 9 at 1:10 AM
Here's Why Emergent Biosolutions Dropped as Much as 11.8% TodayHere's Why Emergent Biosolutions Dropped as Much as 11.8% Today
finance.yahoo.com - November 8 at 3:23 AM
Daniel Abdun-Nabi Sells 31,508 Shares of Emergent Biosolutions, Inc. (EBS) StockDaniel Abdun-Nabi Sells 31,508 Shares of Emergent Biosolutions, Inc. (EBS) Stock
www.americanbankingnews.com - November 7 at 6:32 PM
EBS Crosses Above Average Analyst TargetEBS Crosses Above Average Analyst Target
www.nasdaq.com - November 6 at 7:34 PM
Emergent Biosolutions Shows Market Leadership With Jump To 93 RS RatingEmergent Biosolutions Shows Market Leadership With Jump To 93 RS Rating
finance.yahoo.com - November 6 at 7:33 PM
Emergent Biosolutions beats 3Q profit forecastsEmergent Biosolutions beats 3Q profit forecasts
finance.yahoo.com - November 6 at 7:33 PM
Analyzing Collegium Pharmaceutical (COLL) and Emergent Biosolutions (EBS)Analyzing Collegium Pharmaceutical (COLL) and Emergent Biosolutions (EBS)
www.americanbankingnews.com - November 6 at 1:20 AM
Why Emergent BioSolutions Inc. Jumped Higher Today - Motley FoolWhy Emergent BioSolutions Inc. Jumped Higher Today - Motley Fool
www.fool.com - November 5 at 5:46 PM
Emergent Biosolutions, Inc. (EBS) Releases Quarterly  Earnings Results, Beats Estimates By $0.32 EPSEmergent Biosolutions, Inc. (EBS) Releases Quarterly Earnings Results, Beats Estimates By $0.32 EPS
www.americanbankingnews.com - November 4 at 12:50 PM
Emergent (EBS) Q3 Earnings Beat Estimates, Guidance Raised - NasdaqEmergent (EBS) Q3 Earnings Beat Estimates, Guidance Raised - Nasdaq
www.nasdaq.com - November 3 at 1:24 PM
Emergent (EBS) Q3 Earnings Beat Estimates, Guidance RaisedEmergent (EBS) Q3 Earnings Beat Estimates, Guidance Raised
finance.yahoo.com - November 3 at 1:24 PM
Edited Transcript of EBS earnings conference call or presentation 2-Nov-17 9:00pm GMTEdited Transcript of EBS earnings conference call or presentation 2-Nov-17 9:00pm GMT
finance.yahoo.com - November 3 at 1:24 PM
Emergent BioSolutions Inc. to Host Earnings CallEmergent BioSolutions Inc. to Host Earnings Call
finance.yahoo.com - November 2 at 7:12 PM
Emergent BioSolutions Reports Third Quarter and Nine Months 2017 Financial Results; Raises Calendar Year 2017 GuidanceEmergent BioSolutions Reports Third Quarter and Nine Months 2017 Financial Results; Raises Calendar Year 2017 Guidance
finance.yahoo.com - November 2 at 7:12 PM
Emergent Biosolutions, Inc. (EBS) Scheduled to Post Quarterly Earnings on MondayEmergent Biosolutions, Inc. (EBS) Scheduled to Post Quarterly Earnings on Monday
www.americanbankingnews.com - October 30 at 9:15 AM
Emergent Biosolutions, Inc. (EBS) Upgraded at Zacks Investment ResearchEmergent Biosolutions, Inc. (EBS) Upgraded at Zacks Investment Research
www.americanbankingnews.com - October 25 at 8:32 PM
Emergent Biosolutions, Inc. (EBS) Expected to Announce Quarterly Sales of $127.52 MillionEmergent Biosolutions, Inc. (EBS) Expected to Announce Quarterly Sales of $127.52 Million
www.americanbankingnews.com - October 22 at 11:40 AM
Head to Head Survey: Eyegate Pharmaceuticals (EYEG) and Emergent Biosolutions (EBS)Head to Head Survey: Eyegate Pharmaceuticals (EYEG) and Emergent Biosolutions (EBS)
www.americanbankingnews.com - October 20 at 6:28 AM
Emergent BioSolutions to Release Third Quarter and Nine Months 2017 Financial Results and Conduct a Conference ... - GlobeNewswire (press release)Emergent BioSolutions to Release Third Quarter and Nine Months 2017 Financial Results and Conduct a Conference ... - GlobeNewswire (press release)
globenewswire.com - October 19 at 11:51 PM
Emergent BioSolutions to Release Third Quarter and Nine Months 2017 Financial Results and Conduct a Conference Call on November 2, 2017Emergent BioSolutions to Release Third Quarter and Nine Months 2017 Financial Results and Conduct a Conference Call on November 2, 2017
finance.yahoo.com - October 19 at 6:48 PM
Emergent BioSolutions Completes Acquisition of ACAM2000® Business From Sanofi - GlobeNewswire (press release)Emergent BioSolutions Completes Acquisition of ACAM2000® Business From Sanofi - GlobeNewswire (press release)
globenewswire.com - October 7 at 3:43 PM
Emergent BioSolutions Completes Acquisition of ACAM2000® Business From SanofiEmergent BioSolutions Completes Acquisition of ACAM2000® Business From Sanofi
finance.yahoo.com - October 6 at 6:28 PM
Emergent BioSolutions Completes Acquisition of Raxibacumab, an FDA-Approved Anthrax Monoclonal Antibody, From ... - GlobeNewswire (press release)Emergent BioSolutions Completes Acquisition of Raxibacumab, an FDA-Approved Anthrax Monoclonal Antibody, From ... - GlobeNewswire (press release)
globenewswire.com - October 4 at 4:53 PM
Lifshitz & Miller LLP Announces Investigation of Alere Inc., Emergent ... - PR Newswire (press release)Lifshitz & Miller LLP Announces Investigation of Alere Inc., Emergent ... - PR Newswire (press release)
www.prnewswire.com - October 4 at 4:53 PM
Emergent BioSolutions Awarded U.S. Department of State Contract Valued at Up to $25 Million to Supply Nerve Agent Antidote Auto-InjectorEmergent BioSolutions Awarded U.S. Department of State Contract Valued at Up to $25 Million to Supply Nerve Agent Antidote Auto-Injector
finance.yahoo.com - October 4 at 10:51 AM
Emergent Biosolutions (EBS) "Outperform" Rating Reaffirmed at Wells Fargo & CompanyEmergent Biosolutions' (EBS) "Outperform" Rating Reaffirmed at Wells Fargo & Company
www.americanbankingnews.com - September 30 at 10:28 AM
Emergent Biosolutions, Inc. (EBS) Director Ronald Richard Sells 1,266 SharesEmergent Biosolutions, Inc. (EBS) Director Ronald Richard Sells 1,266 Shares
www.americanbankingnews.com - September 29 at 8:52 PM
Adam Havey Sells 7,885 Shares of Emergent Biosolutions, Inc. (EBS) StockAdam Havey Sells 7,885 Shares of Emergent Biosolutions, Inc. (EBS) Stock
www.americanbankingnews.com - September 29 at 8:02 PM
Emergent Biosolutions, Inc. (EBS) CEO Daniel Abdun-Nabi Sells 15,000 SharesEmergent Biosolutions, Inc. (EBS) CEO Daniel Abdun-Nabi Sells 15,000 Shares
www.americanbankingnews.com - September 29 at 7:38 PM
Fuad El-Hibri Sells 25,000 Shares of Emergent Biosolutions, Inc. (EBS) StockFuad El-Hibri Sells 25,000 Shares of Emergent Biosolutions, Inc. (EBS) Stock
www.americanbankingnews.com - September 29 at 7:38 PM
Emergent Biosolutions, Inc. (EBS) Director Ronald Richard Sells 22,415 SharesEmergent Biosolutions, Inc. (EBS) Director Ronald Richard Sells 22,415 Shares
www.americanbankingnews.com - September 29 at 7:38 PM
Emergent Biosolutions, Inc. (EBS) Chairman Fuad El-Hibri Sells 25,000 SharesEmergent Biosolutions, Inc. (EBS) Chairman Fuad El-Hibri Sells 25,000 Shares
www.americanbankingnews.com - September 29 at 7:16 PM
Emergent BioSolutions: Expected Growth - Seeking AlphaEmergent BioSolutions: Expected Growth - Seeking Alpha
seekingalpha.com - September 29 at 2:58 PM
Emergent BioSolutions to Supply DoD With Chemical Threat Countermeasure RSDL Under Five-Year Follow-On ... - GlobeNewswire (press release)Emergent BioSolutions to Supply DoD With Chemical Threat Countermeasure RSDL Under Five-Year Follow-On ... - GlobeNewswire (press release)
globenewswire.com - September 25 at 3:54 PM
Emergent BioSolutions (EBS) Secures 5-Yr Follow-On $171M Contract to Supply DoD With Chemical Threat Countermeasure RSDLEmergent BioSolutions (EBS) Secures 5-Yr Follow-On $171M Contract to Supply DoD With Chemical Threat Countermeasure RSDL
www.streetinsider.com - September 25 at 11:35 AM

Social Media

Financials

Chart

Emergent Biosolutions (NYSE EBS) Chart for Friday, November, 24, 2017
Loading chart…

This page was last updated on 11/24/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.